Medication Review: Voclosporin Dosing, Administration, Adjustments & Interactions

Join Danielle Gatti Palumbo, Clinical Pharmacist at Northwell Health’s Division of Rheumatology in Long Island, New York, as she provides a comprehensive review of Voclosporin (Lupkynis), an FDA-approved calcineurin inhibitor (CNI) for the treatment of lupus nephritis. This discussion is essential for healthcare professionals, pharmacists, and patients seeking a deeper understanding of how Voclosporin enhances lupus nephritis management while optimizing safety and efficacy.

Voclosporin is a next-generation calcineurin inhibitor that works by inhibiting T-cell activation, reducing the inflammatory response that leads to kidney damage in lupus nephritis. Unlike traditional CNIs like cyclosporine and tacrolimus, Voclosporin features a more consistent pharmacokinetic profile, minimizing variability in drug levels and improving patient outcomes. It is now an integral component of triple therapy in the latest American College of Rheumatology (ACR) 2024 Lupus Nephritis Guidelines, recommended alongside mycophenolate mofetil (MMF) and glucocorticoids for Class III and IV lupus nephritis.

Understanding proper dosing and administration is critical for maximizing Voclosporin’s therapeutic effects. The standard dose is 23.7 mg twice daily, taken on an empty stomach—one hour before or two hours after meals—to ensure optimal absorption. For patients with renal impairment, dose adjustments are required based on estimated glomerular filtration rate (eGFR) to prevent nephrotoxicity. Routine kidney function monitoring is essential, with frequent eGFR assessments to detect early signs of kidney dysfunction.

One of the most important considerations with Voclosporin is its impact on blood pressure regulation, as it can contribute to hypertension. Close monitoring for hypertensive emergencies is crucial, particularly in patients with preexisting cardiovascular conditions. Clinicians must also be aware of drug interactions, especially with CYP3A4 inhibitors and P-glycoprotein substrates, which can alter Voclosporin metabolism and lead to potential toxicity.

Patients and providers should also be informed about common side effects, including neurotoxicity, hyperkalemia, QT prolongation, increased infection risk, and heightened sun sensitivity, all of which require proactive management. Given its potential effects on fetal development, Voclosporin is contraindicated in pregnancy, necessitating careful contraceptive counseling for women of childbearing potential. Breastfeeding is also not recommended while on therapy due to potential drug transfer to breast milk.

As an emerging cornerstone in lupus nephritis treatment, Voclosporin represents a significant advancement in immunosuppressive therapy, offering increased efficacy with a more predictable pharmacokinetic profile. By integrating Voclosporin into treatment plans while carefully monitoring for adverse effects, clinicians can improve long-term kidney function and overall disease management in lupus nephritis patients.

For more expert insights and the latest advancements in rheumatology, visit RhAPP.org or download the RhAPP ACE App for clinical resources and educational updates. Stay informed on cutting-edge treatments shaping the future of autoimmune disease management.